Genotoxicity of several clinically used topoisomerase II inhibitors
- 19 July 2000
- journal article
- Published by Elsevier in Toxicology Letters
- Vol. 116 (1-2) , 7-16
- https://doi.org/10.1016/s0378-4274(00)00192-2
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- In Vitro Evolution of Preferred Topoisomerase II DNA Cleavage SitesJournal of Biological Chemistry, 1999
- Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzymeBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1998
- DNA binding properties of minor groove binders and their influence on the topoisomerase II cleavage reactionJournal of Molecular Recognition, 1997
- The use of L5178Y mouse lymphoma cells to assess the mutagenic, clastogenic and aneugenic properties of chemicalsMutagenesis, 1995
- Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancerJournal of Cellular Biochemistry, 1995
- Human 170 kDa and 180 kDa Topoisomerases II Bind Preferentially to Curved and Left-Handed Linear DNAJournal of Biomolecular Structure and Dynamics, 1994
- potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: Comparison to salmonella responsesEnvironmental and Molecular Mutagenesis, 1994
- When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugsChemical Research in Toxicology, 1993
- Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitroMutagenesis, 1990
- A mutational assay system using the thymidine kinase locus in mouse lymphoma cellsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1972